Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 7/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9911052 | 0.87 | FOLH1 (0.60) | FOLH1 | |
| SCHEMBL19788059 | 0.87 | FOLH1 (0.60) | FOLH1 | |
| SCHEMBL12216484 | 0.79 | EPHX1 (0.61) | FOLH1EPHX1SMN1; SMN2EPHX2NOD1 | |
| SCHEMBL17615103 | 0.79 | FPR2 (0.44) | FOLH1SMN1; SMN2FPR2 | |
| SCHEMBL18253627 | 0.79 | FOLH1 (0.49) | FOLH1EPHX1SMN1; SMN2EPHX2FPR2 | |
| SCHEMBL19788064 | 0.79 | FOLH1 (0.49) | FOLH1EPHX1SMN1; SMN2EPHX2FPR2 | |
| SCHEMBL19359997 | 0.79 | FOLH1 (0.47) | FOLH1EPHX1SMN1; SMN2EPHX2FPR2 | |
| SCHEMBL20910851 | 0.77 | FOLH1 (0.66) | FOLH1 | |
| SCHEMBL26830774 | 0.77 | FOLH1 (0.57) | FOLH1EPHX2 | |
| SCHEMBL19788645 | 0.77 | FOLH1 (0.47) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170049709-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | PFIZER INC. | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170049709-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | CTSA, GAA, EEA1 | FOLH1 135/4885EPHX1 2594/4885SMN1; SMN2 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.